natgillin/translations-raw huggingface dataset:
Chemical and physical in-use stability has been demonstrated for 16 hours at room temperature (up to 30°C). 
Kemična in fizikalna stabilnost med uporabo sta bili dokazani za 16 ur pri sobni temperaturi (do 30 °C).
Approximately 10% of patients had the V30M mutation and early onset of symptoms (< 50 years of age). 
Približno 10 % bolnikov je imelo mutacijo V30M in zgodnji nastop simptomov (starost < 50 let).
INFORMATION IN BRAILLE Onpattro 
PODATKI V BRAILLOVI PISAVI Onpattro
For patients weighing ≥ 100 kg, the maximum recommended dose is 30 mg. 
Za bolnike, ki tehtajo ≥ 100 kg, je največji priporočeni odmerek 30 mg.
• Bupropion, a medicine used to treat depression or to help you to stop smoking 
• bupropion, ki se uporablja za zdravljenje depresije in kot pomoč pri odvajanju od kajenja
Patisiran is metabolized by nucleases to nucleotides of various lengths. 
Patisiran se z nukleazami presnavlja v nukleotide različnih dolžin.
• Suitability of the patient for home infusion; 
• primernosti bolnika za prejemanje infuzij na domu;
• Remove Onpattro from the refrigerator. 
• Zdravilo Onpattro vzemite iz hladilnika.
In general, all findings observed at the end of dosing in the rat and monkey toxicity studies had either a full recovery or were observed with reduced severity at the end of the 60-90 day recovery period, indicating at least partial reversibility. 
Na splošno so vsi izsledki, ki so jih ob koncu odmerjanja opazili v študijah toksičnosti pri podganah in opicah, pokazali popolno okrevanje po koncu 60- do 90-dnevnega obdobja okrevanja, ali pa so opazili njihovo zmanjšanje, kar kaže vsaj delno reverzibilnost.
Liver and spleen were the primary target organs of toxicity in both rats and monkeys. 
Jetra in vranica sta bila primarna ciljna organa toksičnosti pri podganah in opicah.
White to off-white, opalescent, homogeneous solution (pH: 6.3 - 7.5). 
Bela do belkasta, opalescentna, homogena raztopina (pH: 6,3-7,5).
Pharmacotherapeutic group: Other nervous System Drugs; ATC code: N07XX12. 
Farmakoterapevtska skupina: Druga zdravila z delovanjem na živčevje, oznaka ATC: N07XX12
Talk to your doctor or nurse about suitable methods of contraception. 
Z zdravnikom ali medicinsko sestro se pogovorite o primernih načinih kontracepcije.
The net effect on CYP2B6 substrates (e.g., bupropion and efavirenz) in vivo is unknown. 
Neto učinek zdravila na substrate CYP2B6 (npr. bupropion in efavirenz) in vivo ni znan.
• This protein is made mostly in the liver and carries vitamin A and other substances around the body. 
• Ta beljakovina nastaja pretežno v jetrih in po telesu prenaša vitamin A in druge snovi.
When these reactions stop, or get better, your doctor or nurse may decide to start the infusion again. 
Ko se te reakcije ustavijo ali izboljšajo, se lahko zdravnik ali medicinska sestra odloči za ponovno uvedbo infundiranja.
The diluted solution for infusion should be prepared by a healthcare professional using aseptic technique as follows: 
Razredčeno raztopino za infundiranje mora pripraviti zdravstveni delavec z aseptično tehniko, kot sledi:
• Oral paracetamol (500 mg) 
• peroralni paracetamol (500 mg)
Your doctor will tell you how long you need to receive Onpattro. 
Zdravnik vam bo povedal, kako dolgo boste morali prejemati zdravilo Onpattro.
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before starting this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden začnete zdravljenje s tem zdravilom.
This is 0.2% of the recommended maximum daily dietary intake of sodium for an adult. 
To je enako 0,2 % priporočenega največjega dnevnega vnosa natrija s hrano za odrasle osebe.
In the study, 148 patients received Onpattro and 77 patients received placebo. 
V študiji je 148 bolnikov prejemalo zdravilo Onpattro in 77 bolnikov placebo.
bA lower number indicates less impairment/fewer symptoms. 
bManjša številka pomeni manjšo prizadetost/manj simptomov.
Due to the potential teratogenic risk arising from unbalanced vitamin A levels, Onpattro should not be used during pregnancy, unless the clinical condition of the woman requires treatment. 
Zaradi možnosti tveganja za teratogenost, ki izhaja iz neuravnoteženih ravni vitamina A zdravila Onpattro ne smete uporabljati pri nosečnicah, razen če klinično stanje nosečnice zahteva zdravljenje.
Onpattro is for intravenous use. 
Zdravilo Onpattro je za intravensko uporabo.
Patients experienced benefit across all TTR mutations and the full range of disease severity studied. 
Koristi so imeli bolniki z vsemi mutacijami TTR in pri vseh stopnjah bolezni, ki so jih preučevali.
Onpattro has not been studied in patients with prior liver transplant; however, no dose adjustments are considered necessary. 
Zdravila Onpattro niso preučili pri bolnikih s predhodno presaditvijo jeter; kljub temu se upošteva, da prilagoditve odmerkov niso potrebne.
• Withdraw the entire contents of one or more vials into a single sterile syringe. 
• Celotno vsebino ene ali več vial izvlecite v eno sterilno injekcijsko brizgo.
The mean ± SD terminal elimination half-life (t1/2β) of patisiran was 3.2 ± 1.8 days. 
Povprečna končna razpolovna doba izločanja patisirana ± SN (t1/2β) je bila 3,2 ± 1,8 dni.
Onpattro will reduce the level of vitamin A in your blood, which is important for normal development of your unborn child. 
Zdravilo Onpattro bo v vaši krvi zmanjšalo raven vitamina A, ki je pomemben za normalen razvoj vašega nerojenega otroka.
• This means there is less TTR protein in the blood that can form amyloid. 
• To pomeni, da je v telesu manj beljakovine TTR, ki lahko oblikuje amiloid.
• Leakage of the drug into the surrounding tissue at the site of infusion, which may cause swelling or redness 
• iztekanje zdravila v okolno tkivo na mestu infundiranja, kar lahko povzroči oteklino ali pordelost
If you do not have problems with your infusions in the clinic, your doctor may talk with you about a healthcare professional giving you your infusions at home. 
Če nimate težav z infuzijami v bolnišnici, se lahko zdravnik z zdravstvenim delavcem dogovori, da vam bo infuzije dajal doma.
Antidrug antibody titres were low and transient with no evidence of an effect on clinical efficacy, the safety profile, or the pharmacokinetic or pharmacodynamic profiles of Onpattro. 
Titri protiteles proti zdravilu so bili nizki in prehodni, brez dokazanih učinkov na klinično učinkovitost, profil varnosti ali farmakokinetične ali farmakodinamične profile zdravila Onpattro.
How long to use Onpattro 
Kako dolgo uporabljati zdravilo Onpattro
In the unlikely event that you are given too much (an overdose) your doctor or nurse will check you for side effects. 
V malo verjetnem primeru, da boste prejeli preveč zdravila (prevelik odmerek), bosta zdravnik ali medicinska sestra preverila, ali imate neželene učinke.
Pregnancy, breast-feeding and contraception 
Nosečnost, dojenje in kontracepcija
It is important to tell your doctor or nurse if you are taking any of the following medicines as your doctor may need to change the dose: 
Pomembno je, da obvestite zdravnika ali medicinsko sestro, če jemljete katero od naslednjih zdravil, saj vam bo zdravnik morda moral zmanjšati odmerek:
Uncommon: may occur in up to 1 in 100 infusions 
Občasni: pojavijo se lahko pri največ 1 od 100 infuzij
aAll endpoints analysed using the mixed-effect model repeated measures (MMRM) method. 
aVsi opazovani dogodki so bili analizirani z uporabo metod modela mešanega učinka ponovljenih meritev (MMRM - Mixed-Effect Model Repeated Measures).
Dosing is based on actual body weight. 
Odmerjanje mora temeljiti na dejanski telesni masi.
Extravasation was observed in < 0.5% of infusions in clinical studies. 
Ekstravazacijo so v kliničnih študijah opazili pri < 0,5 % infuzij.
Ingredients of Onpattro may pass into breast milk. 
Sestavine zdravila Onpattro lahko prehajajo v materino mleko.
The median patient age at baseline was 62 (range, 24 to 83) years and 74% of patients were male, 26% were female. 
Mediana starosti bolnikov ob izhodišču je bila 62 (razpon 24 do 83) let; 74 % bolnikov je bilo moških in 26 % žensk.
• Body aches or pain, including pain in the back, neck, or joints 
• telesne bolečine, vključno z bolečino v hrbtu, vratu ali sklepih
Ninetythree percent (93%) of Onpattro-treated and 62% of placebo-treated patients completed 18 months of the assigned treatment. 
Triindevetdeset odstotkov (93 %) bolnikov, zdravljenih z zdravilom Onpattro, in 62 % bolnikov, ki je prejemalo placebo, je dokončalo 18 mesecev dodeljenega zdravljenja.
No data are available for patients weighing ≥ 110 kg. 
Podatkov za bolnike s telesno maso ≥ 110 kg ni na voljo.
Prior to the launch of Onpattro in each Member State (MS), the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational materials, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority (NCA). 
Pred prihodom zdravila Onpattro na trg v posamezni državi članici se mora imetnik dovoljenja za promet z zdravilom s pristojnim nacionalnim organom dogovoriti o vsebini in obliki izobraževalnih gradiv, vključno s komunikacijskimi sredstvi, načini razdeljevanja in drugimi vidiki programa.
In case of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and given symptomatic treatment, as appropriate. 
V primeru prevelikega odmerjanja je bolnika priporočljivo spremljati glede znakov ali simptomov neželenih učinkov in ga po potrebi simptomatsko zdraviti.
There are no data on the effects of Onpattro on human fertility. 
Podatkov o učinku zdravila Onpattro na plodnost pri človeku ni.
• Action to take in the event of an IRRs and in case of emergency; 
• ukrepanju v primeru pojava reakcij, povezanih z infuzijo, in v nujnih primerih;
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika ali medicinsko sestro, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
These include anti-histamines, a corticosteroid (a medicine that suppresses inflammation), and a pain reliever. 
Ta vključujejo antihistaminike, kortikosteroid (zdravilo, ki zavira vnetje) in zdravilo za lajšanje bolečin.
Do not mix or dilute with other medicinal products. 
Zdravila ne mešajte in ne redčite z drugimi zdravili.
Suspected extravasation should be managed according to local standard practice for non-vesicants. 
Pri sumu na ekstravazacijo je treba ravnati v skladu z lokalno ustaljeno prakso za učinkovine, ki niso mehurjevci.
Therefore, women of child-bearing age should not be pregnant when starting treatment with Onpattro and should practice effective contraception (see section “Pregnancy, breast-feeding and contraception” below). 
Ženske v rodni dobi zato ne smejo biti noseče, ko se začnejo zdraviti z zdravilom Onpattro, in morajo uporabljati učinkovito kontracepcijo (glejte poglavje »Nosečnost, dojenje in kontracepcija« spodaj).
• Onpattro will be given to you by a doctor or nurse. 
• Zdravilo Onpattro vam bo dal zdravnik ali medicinska sestra.
During the first 60 days of pregnancy, both too high or too low vitamin A levels may be associated with an increased risk of foetal malformation. 
V prvih 60 dneh nosečnosti so lahko previsoke ali prenizke ravni vitamina A povezane s povečanim tveganjem malformacije ploda.
Severe hypersensitivity (e.g., anaphylaxis) to the active substance or any of the excipients listed in section 6.1. 
Huda preobčutljivost (npr. anafilaksa) na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
• The diluted solution of Onpattro should be infused intravenously over approximately 80 minutes at an initial infusion rate of approximately 1 mL/min for the first 15 minutes, followed by an increase to approximately 3 mL/min for the remainder of the infusion. 
• Razredčeno raztopino zdravila Onpattro se infundira intravensko v približno 80-minutnem obdobju z začetno hitrostjo infundiranja približno 1 ml/min prvih 15 minut, nato pa se jo poveča na približno 3 ml/min za preostali čas infundiranja.
The safety and efficacy of Onpattro in children or adolescents < 18 years of age have not been established. 
Varnost in učinkovitost zdravila Onpattro pri otrocih ali mladostnikih, mlajših od 18 let, nista bili dokazani.
Less than 1% of patisiran in the administered dose was recovered intact in urine. 
Manj kot 1 % patisirana iz danega odmerka je bilo v nespremenjeni obliki izoliranega v urinu.
The infusion may need to be slowed down or stopped, and you may need to take other medicines to manage the reaction. 
Morda bo treba infundiranje upočasniti ali ustaviti, vi pa boste morda morali vzeti druga zdravila za zdravljenje reakcije.
Patisiran is not a substrate of cytochrome P450 enzymes. 
Patisiran ni substrat encimov citokroma P450.
Your doctor may tell you to stop taking Onpattro. 
Zdravnik vam bo morda naročil, da prenehate jemati zdravilo Onpattro.
For storage conditions after dilution of the medicinal product, see section 6.3. 
Za pogoje shranjevanja po rekonstituciji zdravila glejte poglavje 6.3.
dmBMI: body mass index (BMI; kg/m2) multiplied by serum albumin (g/L); a higher number indicates better nutritional status; nutritional status favoured Onpattro as early as 3 months. 
dmBMI: indeks telesne mase (BMI; kg/m2) pomnožen z vrednostjo albumina v serumu (g/l); večja številka pomeni boljše stanje prehranjenosti; zdravilo Onpattro je izboljšalo stanje prehranjenosti že v 3. mesecu.
Approximately half (53%) of patients had prior treatment with tafamidis meglumine or diflunisal. 
Približno polovica (53 %) bolnikov se je pred tem zdravila s tafamidis megluminom ali diflunisalom.
The European Medicines Agency has waived the obligation to submit the results of studies with Onpattro in all subsets of the paediatric population in hATTR amyloidosis (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Onpattro za vse podskupine pediatrične populacije pri dedni transtiretinski amiloidozi (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Patient demographics and baseline characteristics were balanced between treatment groups, except that a higher proportion of patients in the Onpattro group had a non-V30M mutation (62% vs. 48%). 
Demografske in izhodiščne značilnosti med skupinama zdravljenja so bile uravnotežene, z izjemo dejstva, da je imel večji delež bolnikov v skupini z zdravilom Onpattro mutacijo, ki ni bila V30M (62 % v primerjavi z 48 %).
As patisiran is not pharmacologically active in rabbits, these effects are not due to reductions in TTR, thyroxine or vitamin A. 
Ker patisiran pri kuncih ni farmakološko aktiven, ti učinki niso posledica zmanjšanja ravni TTR, tiroksina ali vitamina A.
• Irritation or infection of the airways (sinusitis, bronchitis) 
• draženje ali okužba dihal (sinusitis, bronhitis)
Other medicines and Onpattro 
Druga zdravila in zdravilo Onpattro
cA higher number indicates less disability/less impairment. 
cVečja številka pomeni manjšo nezmožnost/manjšo prizadetost.
Alnylam UK Ltd. 
United Kingdom Alnylam UK Ltd.
This medicine contains 3.99 milligrams (mg) of sodium (main component of cooking/table salt) per millilitre (mL). 
To zdravilo vsebuje 3,99 miligramov (mg) natrija (glavne sestavine kuhinjske soli) na mililiter (ml).
Each mL of concentrate contains 3.99 mg sodium. 
En ml koncentrata vsebuje 3,99 mg natrija.
Home infusions should be performed by a healthcare professional. 
Infundiranje zdravila doma mora izvajati zdravstveni delavec.
• Feeling tired (fatigue) 
• občutek utrujenosti (utrujenost)
Very common: may affect more than 1 in 10 people • Swelling of the arms or legs (peripheral oedema) 
Zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnikov • otekanje rok ali nog (periferni edem)
The only adverse reaction resulting in the discontinuation of Onpattro was an infusion-related reaction (0.7%). 
Edini neželen učinek, zaradi katerega so zdravljenje z zdravilom Onpattro prekinili, je bila reakcija, povezana z infuzijo (0,7 %).
With repeat dosing every 3 weeks, mean reductions of serum TTR after 9 and 18 months of treatment were 83% and 84%, respectively. 
S ponavljajočim odmerjanjem vsake 3 tedne je bilo povprečno zmanjšanje ravni TTR v serumu po 9 mesecih zdravljenja 83 % in po 18 mesecih zdravljenja 84 %.
Patients were randomised 2:1 to receive 300 micrograms per kg Onpattro or placebo via intravenous infusion once every 3 weeks for 18 months. 
Bolnike so randomizirali v razmerju 2:1 na prejemanje 300 mikrogramov na kg zdravila Onpattro ali placeba v intravenski infuziji vsake 3 tedne v obdobju 18 mesecev.
Before each infusion you will be given medicines that help to lower the chance of infusion-related reactions (see “Medicines given during treatment with Onpattro” in section 3). 
Pred vsako infuzijo boste prejeli zdravila, ki pomagajo zmanjšati možnosti za reakcije, povezane z infuzijo (glejte »Zdravila, ki se dajejo med zdravljenjem z zdravilom Onpattro« v poglavju 3).
Onpattro Placebo 
Zdravilo Onpattro Placebo
Forty-nine percent (49%) and 50% of patients had a New York Heart Association (NYHA) Class of I or II, respectively. 
Devetinštirideset odstotkov (49 %) bolnikov je bilo uvrščenih v I. razred po funkcijski razvrstitvi Newyorškega združenja za srce (NYHA - New York Heart Association), 50 % pa v II.
• If Onpattro is administered more than 3 days after the missed dose, dosing should be continued every 3 weeks thereafter. 
• Če bolnik zdravilo Onpattro prejme več kot 3 dni po izpuščenem odmerku, naj se odmerjanje nadaljuje vsake 3 tedne po tem dnevu.
The educational material for HCPs should include information about: 
Izobraževalno gradivo za zdravstvene delavce mora vsebovati informacije o:
If you are given more Onpattro than you should receive This medicine will be given to you by your doctor or nurse. 
Če ste prejeli večji odmerek zdravila Onpattro, kot bi smeli To zdravilo vam bo dal zdravnik ali medicinska sestra.
• Onpattro must be diluted prior to intravenous infusion (see instructions in section 6.6). 
• Zdravilo Onpattro je treba pred intravenskim infundiranjem razredčiti (glejte navodila v poglavju 6.6).
Serum TTR reduction was maintained with continued dosing. 
Zmanjšane ravni TTR v serumu so se ohranile z nadaljevanjem odmerjanja.
The most frequently occurring adverse reactions reported in Onpattro-treated patients were peripheral oedema (29.7%) and infusion-related reactions (18.9%). 
Najpogostejši neželeni učinki, o katerih so poročali pri bolnikih, zdravljenih z zdravilom Onpattro, so bili periferni edem (29,7 %) in reakcije, povezane z infuzijo (18,9 %).
The MAH shall ensure that in each MS where Onpattro is marketed, all health care professionals (HCPs) and patients are provided with educational materials in order to ensure the safe and sustainable administration of the product in the home setting, aiming at preventing and/or minimising the important identified risk of Infusion Related Reactions (IRRs). 
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da bodo v vsaki državi članici, kjer je zdravilo Onpattro na trgu, vsi zdravstveni delavci in bolniki prejeli izobraževalna gradiva za zagotovitev varne in trajnostne uporabe zdravila v domačem okolju, s ciljem preprečiti in/ali zmanjšati pomembno ugotovljeno tveganje reakcij, povezanih z infuzijo.
Patients treated with Onpattro experienced statistically significant benefits in all secondary endpoints compared to patients who received placebo (all p <0.001) (Table 2). 
Pri bolnikih, zdravljenih z zdravilom Onpattro, so se pokazale statistično značilne koristi v vseh sekundarnih opazovanih dogodkih v primerjavi z bolniki, ki so prejemali placebo (vsi p < 0,001) (preglednica 2).
• Reddening of the face or body (flushing), warm skin, or rash 
• rdečina obraza ali telesa (zardevanje), topla koža ali izpuščaj
Do not stop treatment with Onpattro unless your doctor tells you to. 
Ne prenehajte se zdraviti z zdravilom Onpattro, če vam tega ne naroči zdravnik.
Approximately 5.5% of DLin-MC3-DMA was recovered after 96 hours as its metabolite (DMBA) in urine. 
Približno 5,5 % lipidne komponente DLin-MC3-DMA je bilo v obliki njenega presnovka (DMBA) po 96 urah izolirane v urinu.
The decision for a patient to receive home infusions should be made after evaluation and recommendation by the treating physician. 
Odločitev o prehodu na infuzije doma mora temeljiti na presoji in priporočilu zdravnika, ki vodi zdravljenje.
Onpattro contains patisiran, a double-stranded small interfering ribonucleic acid (siRNA) that specifically targets a genetically conserved sequence in the 3' untranslated region of all mutant and wild-type TTR mRNA. 
Zdravilo Onpattro vsebuje patisiran, ki je dvoverižna majhna interferenčna ribonukleinska kislina (siRNK - small interfering RNA), ki specifično cilja gensko ohranjeno zaporedje v 3' nekodirajoči regiji vseh mutiranih in nemutiranih mRNK TTR.
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 10 mg/5 mL 
FARMACEVTSKA OBLIKA IN VSEBINA koncentrat za raztopino za infundiranje 10 mg/5 ml
• Onpattro does not contain preservatives. 
• Zdravilo Onpattro ne vsebuje konzervansov.
If you have problems with your vision or any other eye problems whilst using Onpattro, you should talk to your doctor. 
Če imate v času uporabe zdravila Onpattro težave z vidom ali kakršne koli druge težave z očmi, se posvetujte z zdravnikom.
Talk to your doctor about stopping breast-feeding or treatment with Onpattro. 
Z zdravnikom se posvetujte o prenehanju dojenja ali zdravljenja z zdravilom Onpattro.
If a dose is missed, Onpattro should be administered as soon as possible. 
Po izpuščenem odmerku je treba zdravilo Onpattro dati čim prej.
• In people with this illness, abnormally shaped TTR proteins clump together to make deposits called ‘amyloid'. 
• Pri ljudeh s to boleznijo se nenavadno oblikovane beljakovine TTR združujejo v skupke, ki se imenujejo »amiloid«.
Infusion-related reaction 
Reakcije, povezane z infuzijo
• Reasons triggering HCPs to consider whether the patient should stop home infusions and return to the clinic to receive the infusions. 
• razlogih, zaradi katerih morajo zdravstveni delavci razmisliti o tem, ali naj bolnik preneha prejemati infuzije doma in jih ponovno prične prejemati v zdravstveni ustanovi.
Tell your doctor if you have an unplanned pregnancy. 
Obvestite zdravnika, če ste nenačrtovano zanosili.
Table 1: Adverse reactions reported for Onpattro 300 micrograms per kg System Organ Class 
Preglednica 1: Neželeni učinki, o katerih so poročali pri zdravilu Onpattro 300 mikrogramov na kg Organski sistem
4.7 Effects on ability to drive and use machines On the basis of the pharmacodynamic and pharmacokinetic profiles, Onpattro is considered to have no or negligible influence on the ability to drive or use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Na podlagi farmakodinamičnih in farmakokinetičnih profilov velja, da zdravilo Onpattro nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
If you have an infusion-related reaction, your doctor or nurse may slow down or stop your infusion, and you may need to take other medicines to control the symptoms. 
Če imate reakcijo, povezano z infuzijo, lahko zdravnik ali medicinska sestra upočasnita ali ustavita infundiranje in morda boste morali vzeti druga zdravila za obvladovanje simptomov.
• The patient should be observed during the infusion and, if clinically indicated, following the infusion. 
• Bolnika je treba med infundiranjem opazovati, in, če je to klinično indicirano, tudi po infundiranju.
• Cough, feeling short of breath, or other breathing problems 
• kašelj, zasoplost ali druge težave z dihanjem
The components of Onpattro are not inhibitors or inducers of cytochrome P450 enzymes or transporters, except for CYP2B6 (see Section 4.5). 
Sestavine zdravila Onpattro niso zaviralci ali induktorji encimov ali prenašalcev citokroma P450, razen CYP2B6 (glejte poglavje 4.5).